Read-Through for Nonsense Mutations in Type XVII Collagen-Deficient Junctional Epidermolysis Bullosa
Studysummary This article discusses junctional epidermolysis bullosa caused by COL17 deficiency, noting a lack of experimental therapies and the impact of nonsense mutations, but it reports no new clinical results. Our plain-language summary of this paper — not a Tressless recommendation.
This study explores the use of translational read-through-inducing drugs (TRIDs) to treat junctional epidermolysis bullosa (JEB) caused by nonsense mutations in the COL17A1 gene. Seven patients' keratinocytes were treated with gentamicin, paromomycin, G418, amlexanox, and PTC124. Gentamicin, paromomycin, and G418 showed varying effectiveness in inducing COL17 expression, especially in cells with the p.W464* mutation. Gentamicin significantly altered the expression of 1,118 genes, while paromomycin had a milder impact. The study concludes that aminoglycosides can induce read-through of COL17A1 nonsense mutations, suggesting potential personalized therapy for JEB patients.
